This is probably the first question on your mind. You've heard about GLP-1 medications for weight loss. Maybe you've seen the headlines about Ozempic or Wegovy. And now your child's physician is suggesting it might be appropriate for your teenager.
Your instinct to ask about safety isn't just reasonable; it's exactly what a good parent does. Here's what the clinical evidence tells us.
What the research shows
GLP-1 medications have been studied specifically in adolescent populations. The STEP TEENS trial (published in the New England Journal of Medicine in 2022) enrolled 201 adolescents aged 12-17 and followed them for 68 weeks. The results showed significant BMI reduction with a safety profile consistent with what was observed in adults.
The American Academy of Pediatrics (AAP) updated their Clinical Practice Guidelines in 2023 to recommend considering pharmacotherapy, including GLP-1 medications, for adolescents aged 12 and older with obesity, particularly when lifestyle interventions alone haven't achieved sufficient improvement.
These aren't experimental treatments being tried on children. They're FDA-approved medications with adolescent-specific clinical trial data supporting their use.
Common side effects
Like any medication, GLP-1 receptor agonists can cause side effects. Most are gastrointestinal and typically mild, especially when dosing starts low and increases gradually:
The key phrase here is "usually mild and temporary." In the STEP TEENS trial, most gastrointestinal side effects occurred during dose escalation and resolved as the body adjusted. This is precisely why clinical protocols use careful, gradual dose titration over several weeks rather than starting at full dose.
Why supervised care changes the safety equation
The safety of any medication depends heavily on how it's prescribed and monitored. For adolescents, whose bodies are still developing, this is especially true.
This is the difference between "taking a weight loss medication" and "receiving comprehensive, physician-supervised treatment." The medication is one tool within a system designed to protect your child's overall health and development.
Wondering if this applies to your child? The 2-minute eligibility check tells you if Thryvwell could be a fit. No commitment, no payment info.
What we're transparent about
Honesty matters more than marketing. Here's what we tell every family:
Long-term data is still being collected. While current evidence demonstrates safety in the short to medium term (1-2 years), decades-long data on adolescents who begin these medications during childhood doesn't exist yet. These medications are relatively new in pediatric use.
Individual responses vary. Not every adolescent responds the same way. Some experience minimal side effects; others need dose adjustments or medication changes.
This isn't a permanent decision. Treatment can be adjusted, paused, or stopped at any time based on your child's response and your family's preferences.
This is precisely why ongoing clinical supervision, regular lab monitoring, and growth tracking are non-negotiable parts of responsible treatment. We don't prescribe and disappear. We monitor, adjust, and stay involved.
The risk of not treating
Safety conversations often focus exclusively on medication risks. But there's another side: the well-documented risks of untreated adolescent obesity.
- Type 2 diabetes (increasingly diagnosed in teens)
- Metabolic dysfunction-associated steatotic liver disease (MASLD)
- Sleep apnea
- Cardiovascular risk factors
- Joint problems and mobility limitations
- Depression and anxiety
- Social isolation and bullying
- Reduced quality of life
Research shows that 80% of adolescents with obesity will carry it into adulthood, along with its associated health conditions. Early intervention, when the body is still developing and habits are still forming, offers the best opportunity for long-term health improvement.
The question isn't just "is this medication safe?" It's also "what are the consequences of not treating a condition that we know progresses over time?"
How we approach safety at Thryvwell
- Board-certified pediatric clinicians, not general practitioners prescribing outside their specialty
- FDA-approved medications only. Never compounded versions that lack rigorous safety testing
- Gradual dose titration protocols designed specifically for adolescent physiology
- Regular lab monitoring and growth tracking at every stage
- Integrated nutrition guidance to prevent muscle loss and ensure adequate intake
- Behavioral health support to protect your child's relationship with food and body
- Clear communication with your child's pediatrician so everyone is aligned
The bottom line
GLP-1 medications are FDA-approved for adolescents, supported by clinical trial data, and recommended by the American Academy of Pediatrics as part of comprehensive obesity treatment. They are not risk-free (no medication is), but when prescribed and monitored by qualified clinicians, the evidence supports their safety and efficacy in this population.
The most important factor in safety isn't the medication itself. It's the quality of supervision around it. That's what Thryvwell was built to provide.
Sources
- Weghuber, D. et al. "Once-Weekly Semaglutide in Adolescents with Obesity." NEJM (2022)
- American Academy of Pediatrics. "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity." Pediatrics (2023)
- FDA Prescribing Information: Wegovy® (semaglutide) injection
- Kelly, A.S. et al. "Pediatric Obesity Pharmacotherapy." Obesity Reviews (2023)
Have more questions about safety?
Our clinical team is here to answer them. Start with a free eligibility check. No commitment required.
The information on this page is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment. Individual results may vary.
